Associations Between Lead and Cadmium Exposure and Subclinical Cardiovascular Disease in U.S. Adults
Cardiovascular Toxicology · 2025-02 · 25 (2) · 282-293
DOI: 10.1007/s12012-024-09955-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Toxicology, online erschienen am 28.01.2025. Verfasst von Lin Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China. Hauptthemen laut MEDLINE: Cadmium, Lead, Cardiovascular Diseases, Environmental Exposure. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The impact of lead and cadmium exposure on subclinical cardiovascular disease (CVD), indicated by elevated high-sensitivity cardiac troponin (hs-cTnT) and N-terminal pro b-type natriuretic peptide (NT-proBNP) remains uncertain. We analyzed data from participants aged 20 and older, without overt CVD, in the National Health and Nutrition Examination Survey (NHANES; 1999–2004). Elevated lead and cadmium levels were defined as 3.5 μg/dL and 1.0 μg/L (inductively coupled plasma mass spectrometry) and 3.8 μg/dL and 0.9 μg/L (atomic absorption spectrometry), respectively. Elevated hs-cTnT was ≥ 19 ng/L, and elevated NT-proBNP was ≥ 125 pg/mL. Multivariate logistic regression estimated the odds ratios (OR) and 95% confidence intervals (CI) for elevated biomarkers. Among 10,197 participants (mean age 48.8 years; 50.3% female), 5.3% had elevated hs-cTnT and 19.4% had elevated NT-proBNP. Elevated blood lead was associated with increased ORs for elevated hs-cTnT (OR 1.45, 95% CI 1.15–1.84) and NT-proBNP (OR 1.66, 95% CI 1.40–1.97). The corresponding ORs (95% CI) for elevated blood cadmium were 1.33 (1.02, 1.74) and 1.39 (1.18, 1.65). The effect of elevated blood lead on NT-proBNP was particularly pronounced among non-Hispanic Blacks (OR [95% CI], 3.26 [2.24, 4.74]) compared to Mexican Americans (1.46 [0.99, 2.17]) and non-Hispanic Whites (1.31 [1.02, 1.68]) and was stronger in individuals with impaired kidney function (OR [95% CI], 2.31 [1.43, 3.75]) compared to those with normal kidney function (1.44 [1.18, 1.75]). This study first reveals the association between lead and cadmium exposure and subclinical CVD, underscoring the need for targeted preventive measures to reduce cardiovascular risk and improve health outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
- State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Pokfulam, Hong Kong, China.
- Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China. mycheung@hku.hk.
- State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Pokfulam, Hong Kong, China. mycheung@hku.hk.
- Institute of Cardiovascular Science and Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China. mycheung@hku.hk.
- Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong, China. mycheung@hku.hk.
Zitieren
APA
Liu, L., Xu, A., & Cheung, B. M. Y. (2025). Associations Between Lead and Cadmium Exposure and Subclinical Cardiovascular Disease in U.S. Adults. Cardiovascular Toxicology, 25(2), 282-293. https://doi.org/10.1007/s12012-024-09955-1
Vancouver
Liu L, Xu A, Cheung BMY. Associations Between Lead and Cadmium Exposure and Subclinical Cardiovascular Disease in U.S. Adults. Cardiovascular Toxicology. 2025;25(2):282-293. doi:10.1007/s12012-024-09955-1
BibTeX
@article{Liu2025,
author = {Liu, Lin and Xu, Aimin and Cheung, Bernard M Y},
title = {Associations Between Lead and Cadmium Exposure and Subclinical Cardiovascular Disease in U.S. Adults},
journal = {Cardiovascular Toxicology},
year = {2025},
volume = {25},
number = {2},
pages = {282--293},
doi = {10.1007/s12012-024-09955-1}
}
EUVIMED